EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention

Ravikanth Maddipati

Journal of Clinical Investigation · 15.07.2025 · 135 (14)

DOI: 10.1172/jci191943 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.07.2025. Verfasst von Ravikanth Maddipati. Beteiligte Einrichtung: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tumor Microenvironment, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, BLRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal cancers, with metastasis as the primary driver of mortality. While metastatic mechanisms are shared across malignancies, PDAC metastasis poses unique therapeutic challenges due to the presence of extensive tumor heterogeneity, desmoplasia, and immunosuppression — features that enable diverse migratory behaviors and therapeutic resistance. Recent advances have shown that metastatic progression in PDAC emerges from dynamic interactions between tumor cell–intrinsic and microenvironmental factors, each adapting to evolving stressors throughout the metastatic cascade. In the primary tumor, genomic instability and epigenetic reprogramming generate subclones with heightened invasive potential, while dense stromal reactions and myeloid-dominated immune suppression facilitate escape. During circulation, PDAC cells employ distinctive survival strategies through homotypic clustering and heterotypic interactions with blood components. At distant sites, PDAC cells adapt to organ-specific microenvironments through context-dependent metabolic and immune modulation, resulting in phenotypes that diverge from the primary tumor. In this Review, we examine how tumor-stroma crosstalk mechanisms shape metastatic progression in PDAC, provide a framework for understanding why conventional therapies often fail against metastatic disease, and highlight emerging opportunities for stage- and site-specific therapeutic interventions that target these unique adaptations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsTumor MicroenvironmentCarcinoma, Pancreatic DuctalHumansNeoplasm MetastasisAnimals

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Veterans Administration North Texas Health Care System, Dallas, Texas, USA.
  • Children's Medical Center Research Institute and.
  • Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Förderung

  • NCI NIH HHS
  • BLRD VA

Zitieren

APA

Maddipati, R. (2025). Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention. Journal of Clinical Investigation, 135(14). https://doi.org/10.1172/jci191943

Vancouver

Maddipati R. Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention. Journal of Clinical Investigation. 2025;135(14). doi:10.1172/jci191943

BibTeX
@article{Maddipati2025,
  author = {Maddipati, Ravikanth},
  title = {Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {14},
  doi = {10.1172/jci191943}
}
Kostenlos starten →